Emcure Pharmaceuticals reported strong financial results for the first quarter of FY26, demonstrating impressive growth in both domestic and international businesses.

The company posted a 16 percent year-on-year (YoY) growth in revenue, with revenue from operations rising to INR 2,101 crore, up from INR 1,815 crore in the same quarter last year.

Profit After Tax (PAT) surged 41 percent YoY to INR 215 crore, while EBITDA rose 20.1 percent YoY to INR 404 crore, with EBITDA margins expanding to 19.2 percent.

Emcure’s international business led the growth, delivering sales of INR 1,106 crore, up 22.1 percent YoY. This was driven by a 42 percent growth in its Rest of the World (RoW) markets, a 16.4 percent increase in Canada business, supported by new product launches and market share gains, and a 12.8 percent rise in Europe, which saw early benefits from recent launches.

The company’s domestic business grew 9.4 percent YoY, reaching INR 995 crore in revenue, supported by strong performance across key therapies and aided by new initiatives in derma and over-the-counter (OTC) segments.

During the quarter, the company further strengthened its domestic business by expanding its strategic partnership with Sanofi. Emcure will be marketing and distributing the French pharma major’s oral anti-diabetic portfolio in addition to the cardiovascular portfolio.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said, “We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets through in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast-growing metabolic segment.”

Mehta highlighted that they have a strong product pipeline for both domestic and international markets, which will fuel future growth.

“We remain focused on improving efficiencies to drive sustained improvement in margins,” he added.

Headquartered in Pune, Emcure is a research-driven pharmaceutical company operating in over 70 countries, including Europe and Canada, with a diverse portfolio spanning major therapeutic areas.